ABBV240816C140000
- 49.36
- +3.32+7.21%
AbbVie Newsroom
AbbVie Analyst Ratings
Morgan Stanley Adjusts Price Target on AbbVie to $218 From $211, Maintains Overweight Rating
AbbVie Analyst Ratings
Daiwa Adjusts Price Target on AbbVie to $190 From $171
HSBC Adjusts Price Target on AbbVie to $215 From $185
Evercore Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $192
BNP Paribas Exane Adjusts Price Target on AbbVie to $193 From $172
Evercore ISI Sticks to Its Buy Rating for AbbVie (ABBV)
Analysts' Top Healthcare Picks: Edwards Lifesciences (EW), AbbVie (ABBV)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Regeneron (REGN), AptarGroup (ATR) and AbbVie (ABBV)
A Quick Look at Today's Ratings for AbbVie(ABBV.US), With a Forecast Between $200 to $211
Cantor Fitzgerald Reiterates Overweight on AbbVie, Maintains $200 Price Target
A Quick Look at Today's Ratings for AbbVie(ABBV.US), With a Forecast Between $200 to $214
Morgan Stanley Adjusts AbbVie Price Target to $211 From $196
AbbVie Analyst Ratings
Buy Rating Affirmed for AbbVie Amidst Strong Financials and Strategic Management
Barclays Reaffirms Their Buy Rating on AbbVie (ABBV)
Piper Sandler Adjusts Price Target on AbbVie to $196 From $190
Piper Sandler Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $190
Piper Sandler Sticks to Its Buy Rating for AbbVie (ABBV)